AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%
Last update at 2024-04-18T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8268.00M | 7798.00M | 13804.00M | 2822.00M | 4405.00M |
| Minority interest | -113.00000M | -56.00000M | 146.00M | 174.00M | 159.00M |
| Net income | 6720.00M | 6223.00M | 12314.00M | 2806.00M | 4306.00M |
| Selling general administrative | 10492.00M | 9555.00M | 9390.00M | 9883.00M | 9859.00M |
| Selling and marketing expenses | - | - | 9390.00M | 9883.00M | 9859.00M |
| Gross profit | 31694.00M | 26920.00M | 25212.00M | 25655.00M | 24242.00M |
| Reconciled depreciation | 2053.00M | 1580.00M | 3684.00M | 7452.00M | 4279.00M |
| Ebit | 11717.00M | 8126.00M | 8082.00M | 7694.00M | 6921.00M |
| Ebitda | 13770.00M | 10762.00M | 9763.00M | 9840.00M | 9091.00M |
| Depreciation and amortization | 2053.00M | 2636.00M | 1681.00M | 2146.00M | 2170.00M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 11717.00M | 8126.00M | 8082.00M | 7694.00M | 4676.00M |
| Other operating expenses | 33508.00M | 30028.00M | 29476.00M | 30405.00M | 29422.00M |
| Interest expense | 440.00M | 368.00M | 390.00M | 444.00M | 435.00M |
| Tax provision | 1503.00M | 1558.00M | 1813.00M | 139.00M | 481.00M |
| Interest income | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M |
| Net interest income | -234.00000M | -328.00000M | -337.00000M | -303.00000M | -271.00000M |
| Extraordinary items | - | - | - | -101.00000M | -13.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 1503.00M | 1558.00M | 1813.00M | 139.00M | 481.00M |
| Total revenue | 45389.00M | 39175.00M | 37369.00M | 37631.00M | 35677.00M |
| Total operating expenses | 19813.00M | 17773.00M | 17319.00M | 18429.00M | 17987.00M |
| Cost of revenue | 13695.00M | 12255.00M | 12157.00M | 11976.00M | 11435.00M |
| Total other income expense net | -3449.00000M | -328.00000M | 5722.00M | -4872.00000M | -1579.00000M |
| Discontinued operations | - | - | - | -101.00000M | -13.00000M |
| Net income from continuing ops | 6833.00M | 6279.00M | 12350.00M | 2938.00M | 4423.00M |
| Net income applicable to common shares | 8371.00M | 6223.00M | 12314.00M | 2806.00M | 4306.00M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 124585.00M | 120242.00M | 114529.00M | 112736.00M | 111408.00M |
| Intangible assets | 21640.00M | 21407.00M | 18421.00M | 16572.00M | 21889.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 85.00M | 89.00M | 83.00M | -9758.00000M | 701.00M |
| Total liab | 51073.00M | 51211.00M | 51382.00M | 53628.00M | 52373.00M |
| Total stockholder equity | 73144.00M | 68681.00M | 63001.00M | 58934.00M | 58876.00M |
| Deferred long term liab | 6226.00M | 7730.00M | 6092.00M | 2334.00M | 4744.00M |
| Other current liab | 425.00M | 127.00M | 32.00M | 298.00M | -392.00000M |
| Common stock | 2522.00M | 2527.00M | 2518.00M | 2508.00M | 2495.00M |
| Capital stock | 2522.00M | 2527.00M | 2518.00M | 2508.00M | 2495.00M |
| Retained earnings | - | - | - | 0.00000M | 0.00000M |
| Other liab | 10835.00M | 10954.00M | 11426.00M | 12123.00M | 12990.00M |
| Good will | 49892.00M | 48056.00M | 44364.00M | 44519.00M | 44235.00M |
| Other assets | 12856.00M | 13455.00M | 11358.00M | 8760.00M | 10199.00M |
| Cash | 12736.00M | 10098.00M | 13915.00M | 9427.00M | 6925.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 23974.00M | 21295.00M | 19280.00M | 20387.00M | 17376.00M |
| Current deferred revenue | 264.00M | 319.00M | 822.00M | - | 733.00M |
| Net debt | 8476.00M | 12316.00M | 9760.00M | 16506.00M | 17715.00M |
| Short term debt | 4451.00M | 3452.00M | 2999.00M | 4815.00M | 2633.00M |
| Short long term debt | 4174.00M | 3183.00M | 2767.00M | 4554.00M | 2633.00M |
| Short long term debt total | 21212.00M | 22414.00M | 23675.00M | 25933.00M | 24640.00M |
| Other stockholder equity | 2437.00M | 3998.00M | 3795.00M | 3854.00M | 3443.00M |
| Property plant equipment | 11684.00M | 11976.00M | 10563.00M | 11017.00M | 9651.00M |
| Total current assets | 34111.00M | 30653.00M | 33786.00M | 28936.00M | 24647.00M |
| Long term investments | 9153.00M | 7975.00M | 7147.00M | 5266.00M | 5531.00M |
| Net tangible assets | 9478.00M | 6948.00M | 6308.00M | 177.00M | -2504.00000M |
| Short term investments | 664.00M | 1054.00M | 900.00M | 426.00M | 199.00M |
| Net receivables | 374.00M | 612.00M | 1208.00M | 10083.00M | 9345.00M |
| Long term debt | 14857.00M | 17123.00M | 19745.00M | 20131.00M | 22007.00M |
| Inventory | 20916.00M | 19854.00M | 18580.00M | 19184.00M | 17654.00M |
| Accounts payable | 18834.00M | 17397.00M | 15427.00M | 15274.00M | 14402.00M |
| Total permanent equity | - | - | - | 0.00000M | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.00000M | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | 0.00000M | 0.00000M |
| Accumulated other comprehensive income | 68185.00M | 62156.00M | 56688.00M | 52572.00M | 52938.00M |
| Additional paid in capital | - | - | - | 0.00000M | 0.00000M |
| Common stock total equity | - | - | 2518.00M | 2508.00M | 2495.00M |
| Preferred stock total equity | - | - | - | 0.00000M | 0.00000M |
| Retained earnings total equity | - | - | - | 0.00000M | 0.00000M |
| Treasury stock | - | - | - | -9.00000M | -153.00000M |
| Accumulated amortization | - | - | - | 0.00000M | 0.00000M |
| Non currrent assets other | -5139.00000M | -4423.00000M | -3964.00000M | -5434.00000M | -4613.00000M |
| Deferred long term asset charges | - | - | - | 0.00000M | 0.00000M |
| Non current assets total | 90474.00M | 89589.00M | 80743.00M | 83800.00M | 86761.00M |
| Capital lease obligations | 2181.00M | 2108.00M | 1163.00M | 1248.00M | 0.00000M |
| Long term debt total | - | - | - | 21168.00M | 22071.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2075.00000M | -311.00000M | 10233.00M | -1058.00000M | -12872.00000M |
| Change to liabilities | 452.00M | 451.00M | 86.00M | 169.00M | 270.00M |
| Total cashflows from investing activities | -2075.00000M | -7298.00000M | 3588.00M | -1212.00000M | -12866.00000M |
| Net borrowings | -1245.00000M | -2804.00000M | -1885.00000M | -491.00000M | 8722.00M |
| Total cash from financing activities | -5821.00000M | -7056.00000M | -6485.00000M | -4039.00000M | 3928.00M |
| Change to operating activities | 545.00M | 1130.00M | 316.00M | 421.00M | -814.00000M |
| Net income | 8371.00M | 6223.00M | 12294.00M | 2754.00M | 4306.00M |
| Change in cash | 2638.00M | -3817.00000M | 4488.00M | 2502.00M | -3390.00000M |
| Begin period cash flow | 10098.00M | 13915.00M | 9427.00M | 6925.00M | 10315.00M |
| End period cash flow | 12736.00M | 10098.00M | 13915.00M | 9427.00M | 6925.00M |
| Total cash from operating activities | 10526.00M | 10522.00M | 7418.00M | 7715.00M | 5547.00M |
| Issuance of capital stock | 188.00M | 186.00M | 203.00M | 162.00M | 177.00M |
| Depreciation | 3365.00M | 3001.00M | 3186.00M | 3593.00M | 3339.00M |
| Other cashflows from investing activities | -16.00000M | -68.00000M | -113.00000M | -94.00000M | -58.00000M |
| Dividends paid | -4168.00000M | -4008.00000M | -3937.00000M | -3834.00000M | 3773.00M |
| Change to inventory | -927.00000M | -357.00000M | -593.00000M | -547.00000M | -701.00000M |
| Change to account receivables | -777.00000M | 185.00M | -134.00000M | -462.00000M | -35.00000M |
| Sale purchase of stock | -497.00000M | -382.00000M | -822.00000M | -9.00000M | -1101.00000M |
| Other cashflows from financing activities | 1665.00M | -462.00000M | 2257.00M | 1976.00M | 7701.00M |
| Change to netincome | -600.00000M | -230.00000M | -7851.00000M | 1630.00M | -933.00000M |
| Capital expenditures | 1606.00M | 1479.00M | 1254.00M | 1323.00M | 1415.00M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -1704.00000M | 1409.00M | -325.00000M | -419.00000M | -1280.00000M |
| Stock based compensation | 245.00M | 244.00M | 274.00M | 252.00M | 284.00M |
| Other non cash items | 827.00M | 1.00M | -7797.00000M | 3288.00M | -2098.00000M |
| Free cash flow | 8920.00M | 9043.00M | 6164.00M | 6392.00M | 4132.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SNY Sanofi ADR |
-0.72 1.56% | 45.39 | 12.35 | 10.91 | 2.69 | 1.52 | 3.00 | 9.61 |
| LLY Eli Lilly and Company |
-4.82 0.64% | 745.95 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
0.97 0.67% | 145.74 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
0.41 0.25% | 164.66 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
-0.16 0.13% | 125.21 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
54, Rue La BoEtie, Paris, France, 75008
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Hudson | CEO & Director | 1967 |
| Mr. Jean-Baptiste Chasseloup de Chatillon | Exec. VP & CFO | 1965 |
| Mr. Laurent Gilhodes | Principal Accounting Officer and VP of Corp. Accounting | NA |
| Mr. Bruno Ménard | Chief Information officer | NA |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care | NA |
| Eva Schaefer-Jansen | Head of Investor Relations | NA |
| Mr. Dante Beccaria | Global Compliance Officer & VP | NA |
| Mr. Roy Papatheodorou | Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity | 1978 |
| Mr. Josep Catlla | Head of Communications | NA |
| Mr. Pierre Chancel | Sr. VP of Global Diabetes and Sr. VP of Global Marketing | 1957 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...